Skip to content

Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults

Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults: a Randomized, Double-blinded, Placebo-controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03775837
Enrollment
60
Registered
2018-12-14
Start date
2018-12-01
Completion date
2025-12-31
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Brief summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Panax Ginseng C.A. Mey Extract on liver function in adults for 8 weeks.

Detailed description

Previous studies have indicated that Panax Ginseng C.A. Mey Extract may have the ability to improve liver function. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the Panax Ginseng C.A. Mey Extract on liver function in adults; the safety of the compound are also evaluate. The Investigators examine AST, ALT, GGT, and other metabolic parameters at baseline, as well as after 4 and 8 weeks of intervention. Sixty adults were administered either 600 mg of Panax Ginseng C.A. Mey Extract or a placebo each day for 8 weeks;

Interventions

DIETARY_SUPPLEMENTPanax Ginseng C.A. Mey Extract group

This group takes Panax Ginseng C.A. Mey Extract for 8 weeks

DIETARY_SUPPLEMENTPlacebo group

This group takes placebo for 8 weeks

Sponsors

Pusan National University Yangsan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* ALT ranging from upper limit of reference to three times of upper limit

Exclusion criteria

* Abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dL) * Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL) * History of viral hepatitis or cancer * Uncontrolled hypertension * History of serious cardiac disease such as angina or myocardial infarction * History of gastrectomy * History of medication for psychiatric disease * Administration of oriental medicine including herbs within the past 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
Alanine aminotransferase8 weeksAlanine aminotransferase

Secondary

MeasureTime frameDescription
Aspartate aminotransferase8 weeksAspartate aminotransferase
Gamma-glutamyl transferase8 weeksGamma-glutamyl transferase

Countries

South Korea

Contacts

Primary ContactSang Yeoup Lee
saylee@pnu.edu360-2860
Backup ContactYe Li Lee
yeri1230@gmail.com360-2860

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026